Core Insights - The company reported a revenue of 7.19 billion in 2024, a year-on-year decline of 15.8%, with a net loss attributable to shareholders of 381 million, transitioning from profit to loss [1] - The company aims to enhance operational efficiency and reduce costs, achieving a 15.5% decrease in reagent costs [2] - The company maintains its profit forecasts for 2025 and 2026, with a target price of 31.84, indicating a potential upside of 15.2% from the current stock price [3] Financial Performance - In 2024, the company's third-party medical diagnostic service revenue was 6.63 billion, down 14.2%, with a gross margin of 32.8%, a decrease of 2.7 percentage points [1] - For Q1 2025, the revenue was 1.47 billion, a decline of 20.4%, with a net loss of 27.79 million [1] - The company recorded credit impairment losses of 619 million in 2024 and 106 million in Q1 2025, impacting net profit [1] Operational Developments - The company established two production centers in Changsha and Zhengzhou, focusing on centralized and scaled production of various technology platforms [2] - The company launched its digital pathology system KMDP, serving over 450 clients, and developed an integrated service platform with over 570,000 registered users [2] - The company introduced five data products on the Guangzhou Data Exchange and collaborated with Kangrun Bio to develop an AI-based immunofluorescence detection platform [2] Market Position - Despite short-term pressures in the industry, the company achieved a 2.94% increase in specimen testing volume in 2024, maintaining a leading market share [1] - The company's comprehensive gross margin improved to 33.2% in Q1 2025, up 1.2 percentage points year-on-year [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300439 证券简称：美康生物 公告编号：2025-015 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 立信会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所未变更。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以2024年12月31日的总股本383,949,815股为基数，向全 体股东每10股派发现金红利1.35元（含税），送红股0股（含税），以资本公积金向全体股东每10股转 增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （1）公司主要业务 公司主要从事体外诊断产品的研发 ...